The University of Texas Health Science Center at San Antonio
Who can join
Adults 30 to 70, any sex, with Diabetes Mellitus, Type 2. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
GFR (Glomerular Filtration Rate) Change After TreatmentPrimary· 4 months
Change from baseline in GFR after treatment from baseline to 4 months
Group
Value
95% CI
Dapagliflozin/Hyperfiltration
22
± 6
Metformin/Hyperfiltration
1
± 5
Dapagliflozin/Normofiltration
8
± 3
Metformin/Normofiltration
0
± 4
Adverse events — posted to ClinicalTrials.gov
Time frame: All adverse events were recorded during the entire 4 months period of the study.
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
The investigators propose to treat newly diagnosed, hyperfiltering T2DM patients with or without microalbuminuria with dapagliflozin or metformin for 4 months. The metformin-treated group will serve as controls for improved glycemic control, since the investigators have shown that insulin therapy to normalize A1c reduces hyperfiltration and kidney size in T1DM patients.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
NCT06851962 — Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.
· Phase 4
· active not recruiting
Other recruiting trials for Diabetes Mellitus, Type 2
Currently open trials in the same condition.
NCT07415954 — A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2
· Phase 2
· recruiting
NCT07532863 — A Real-world Study to Investigate Cardiovascular Risk Profile Among Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) Part
· recruiting
NCT07336329 — Continuous Glucose Monitoring in Non-Insulin Treated Type 2 Diabetes: Continuous vs. Periodic Use
· NA
· recruiting
NCT07242469 — A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006)
· Phase 1
· recruiting
NCT07444203 — Transformative Research in Diabetic Nephropathy 2.0
· recruiting
Other The University of Texas Health Science Center at San Antonio trials
Trials by the same sponsor.
NCT07280897 — SCIPI Implementation and Evaluation: A Multi-site Proof-of-Concept Pilot Trial
· NA
· not yet recruiting
NCT07053319 — SGLT2i, Pioglitazone, and Ketone Production in T2D
· Phase 1
· recruiting
NCT07056699 — SGLT2i, Pioglitazone, and Ketone Production in T1D
· Phase 3
· not yet recruiting
NCT06609343 — Bupropion for Fatigue in End-stage Kidney Disease Patients on Hemodialysis
· Phase 1, PHASE2
· not yet recruiting
NCT07437053 — Sarcopenia in Chronic Kidney Disease (CKD) Patients
· EARLY_PHASE1
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The University of Texas Health Science Center at San Antonio
Last refreshed: 30 November 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02911792.